PAGE 2 IMS HEALTH REAL-WORLD EVIDENCE SOLUTIONS

INSIGHTS HOW IS ONCOLOGY TREATMENT EVOLVING?

ACCESSPOINT • VOLUME 6 • ISSUE 12 PAGE 3

0

20

40

60

80

100

Upcoming Development by Tumor TypeLaunches by Year0

5

10

15

20

25

30

20172016 2018 2019 2020 >2020

The Current Oncology Pipeline:Development & Launch

Exceptional launch activity increases options for patients but requires a greater understanding of treatment pathways and patient segments for payers and clinicians. The sheer volume of potential new products drives a need to reassess the way information about these expanded options is conveyed to stakeholders.

These figures are estimates based on phase III completion dates. The actual number of launches will depend on successful trial completion and FDA approval. Products in phase II that could successfully move through launch are not included.

Intense R&D activity reflects tremendous market growth and an increased understanding of oncology. Of the 100+ molecules in phase III development, 68% are targeted agents, illustrating how oncology will become even more specialized.

BreastCancer

Non-Small Cell Lung Cancer

80%

10%

10%

OvarianCancer

Acute Myeloid Leukemia

GastricCancer

8%

46%

23%

23%

66%

17%

17%

66%

17%

17%

80%

20%

50%

50%

HepatocellularCarcinoma

Melanoma

38%

49%

7%3%3%

75%

25%

68%

26%

100%

ColorectalCancer

61%

13%

13%

13%

Renal Cell Cancer

Non-HodgkinLymphoma

Others

4

66

5 4

19 19 13 8

4 29

6%

57%

11%

26%

2%2% 2%

11

3312%

73%3%12%

58

53%

34%

13% 54%42% 4%

61%35% 4%

47

24

23

73%

18%

9%

70%20%

10%

47% 53%

83%17%58%

14%

14%

14%

41%

3%

56% 39

10

7 6

2986%7%7%

20%

15

Launch activity over the next 4 years promises a range of new options across solid and hematological malignancies

Note: Represents the top 10 tumors by number of launches from 2016-2020

Number of LaunchesAcute Myeloid

Leukemia

47%33% 15

GastricCancer

20%

Hepato-cellular

Carcinoma

MelanomaBreastCancer

80%

10%

10% 10

OvarianCancer

ColorectalCancer

100% 8

Chronic Lymphocytic

Leukemia

100% 10

Non-HodgkinLymphoma

Non-Small Cell Lung

Cancer

Source all data: IMS R&D Focus; www.clinicaltrials.gov

Vaccine

Targeted

Oncolytic Virus

Immuno-oncology

Others

Chemotherapy

Activity Breakdown

original data graphs, always copy/paste to edit

scale 80% and additional 80% smaller to create shading

Unprecedented launches signal new needs for stakeholder engagement

68%

2%

7%

18%

VaccineImmuno-oncologyTargeted Chemotherapy Oncolytic Virus Other

n=101

Saurabh Kumar, MD, MBA – Senior Manager, Global Delivery Center, IMS Health, Skumar1@in.imshealth.com Divya Dhingra, MSC – Associate Consultant, IMS Health, Ddhingra@in.imshealth.com

2016 2018 2019 2020 >20202017

3% 2%

Total Clinical Activity

18%